Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lepodisiran in adults with elevated Lipoprotein(a) and cardiovascular risk
NCT06292013Phase 3Active, not recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Mar 2024
- Primary completion
- Mar 2029
- Modality
- Conjugated siRNA, Chemically Modified siRNA
- Countries
- 28
01
Overview
A Phase 3 trial of lepodisiran in atherosclerotic cardiovascular disease (ASCVD), elevated lipoprotein(a) (Lp(a)), sponsored by Eli Lilly and Company. Started Mar 2024; status: active, not recruiting.
02
Drugs
lepodisiran
03
Conditions
atherosclerotic cardiovascular disease (ASCVD)elevated lipoprotein(a) (Lp(a))
Beyond the preview
Go deeper on NCT06292013.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06292013.